Study of Telintra for Treatment of Chemotherapy Induced Neutropenia in Patients With Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

ezatiostat hydrochloride (Telintra®)

4500 mg orally per day in two divided doses

Trial Locations (24)

10467

Montefiore Medical Center, The Bronx

30045

Suburban Hematology-Oncology Associates, PC, Lawrenceville

32174

Florida Hospital Cancer Institute, Ormand Beach

33308

Broward Oncology Associates, Fort Lauderdale

33805

Lakeland Regional Cancer Center, Lakeland

34452

Nature Coast Clinical Research, Inverness

44106

Case Medical Center-University Hospitals, Cleveland

60435

Joliet Oncology/Hematology Associates, Ltd., Joliet

61401

Medical & Surgical Specialists, Galesburg

73104

The University of Oklahoma Health Sciences Center, Oklahoma City

89052

Comprehensive Cancer Centers of Nevada, Henderson

90095

UCLA Medical Center, Los Angeles

90640

Clinical Trials and Research Associates, Inc., Montebello

91325

North Valley Hematology/Oncology Medical Group, Northridge

91505

Providence St. Joseph Medical Center, Burbank

91750

Wilshire Oncology Medical Group, La Verne

91801

Central Hematology Oncology Medical Group, Alhambra

92801

Pacific Cancer Medical Center, Inc., Anaheim

92835

St. Jude Heritage Healthcare, Fullerton

93030

Ventura County Hematology-Oncology Specialists, Oxnard

93105

Samsum Clinic, Santa Barbara

Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara

93454

Central Coast Medical Oncology Corporation, Santa Maria

29572-4128

Coastal Cancer Center, Myrtle Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Telik

INDUSTRY